ID   10A-KRAS(G12V) clone 1
AC   CVCL_F6KT
SY   10A-KRAS (G12V) clone 1
RX   PubMed=26497685;
CC   Characteristics: Not tumorigenic in nude-Foxn1nu mice (PubMed=26497685).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transduction; Gene=HGNC; HGNC:6407; KRAS (Note=With p.Gly12Val).
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P00552; Klebsiella pneumoniae transposon Tn5 neo.
CC   Derived from site: In situ; Breast, epithelium; UBERON=UBERON_0008367.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0598 ! MCF-10A
SX   Female
AG   36Y
CA   Spontaneously immortalized cell line
DT   Created: 22-10-26; Last updated: 22-10-26; Version: 1
CH   CVCL_F6KX ! 10A-KRAS(G12V)-Luc
//
RX   PubMed=26497685; DOI=10.18632/oncotarget.6159; PMCID=PMC4742101;
RA   Thompson, Keyata N.
RA   Whipple, Rebecca A.
RA   Yoon, Jennifer R.
RA   Lipsky, Michael
RA   Charpentier, Monica S.
RA   Boggs, Amanda E.
RA   Chakrabarti, Kristi R.
RA   Bhandary, Lekhana
RA   Hessler, Lindsay K.
RA   Martin, Stuart S.
RA   Vitolo, Michele I.
RT   "The combinatorial activation of the PI3K and Ras/MAPK pathways is
RT   sufficient for aggressive tumor formation, while individual pathway
RT   activation supports cell persistence.";
RL   Oncotarget 6:35231-35246(2015).
//